Literature DB >> 29523924

The central zone has increased 68Ga-PSMA-11 uptake: "Mickey Mouse ears" can be hot on 68Ga-PSMA-11 PET.

Daniele A Pizzuto1,2, Julian Müller1, Urs Mühlematter1, Niels J Rupp3, Antonia Töpfer3, Ashkan Mortezavi4, Hannes Nagel1, Benedikt Kranzbühler4, Daniel Eberli4, Irene A Burger5.   

Abstract

PURPOSE: Given the good correlation between PSMA expression and intraglandular tumour aggressiveness based on immunohistochemistry, there is increasing interest in 68Ga-PSMA-11 PET/MRI for staging prostate cancer (PCA). Therefore, accurate knowledge of prostate anatomy as well as normal distribution of PSMA within the prostate gland is becoming essential. The aim of this study was to investigate the physiological intraprostatic distribution of 68Ga-PSMA-11.
METHODS: We retrospectively analysed all patients who underwent a staging 68Ga-PSMA-11 PET/MRI scan between June 2016 and January 2018 for high-risk PCA, underwent radical prostatectomy in our institution, and gave written consent for further data analysis. In each patient, standardized volumes of interest (VOIs) were placed bilaterally in the central, transition and peripheral zones within the zonal anatomy according to T2 weighted sequences in the axial and coronal planes. VOIs were only placed if they were safely within healthy tissue without spillover from the PCA. SUVmax and SUVmean were determined and their differences among the regions were assessed using the Wilcoxon signed-ranks test.
RESULTS: Of 283 consecutive patients scanned with 68Ga-PSMA-11 PET/MR, 31 were analysed. A total of 133 VOIs were placed, 46 in the central zone, 41 in the transition zone and 46 in the peripheral zone. Differences in SUVmax between the central zone (mean 3.9 ± 0.58) and transition zone (mean 3.2 ± 0.59) and between the central zone and peripheral zone (mean 2.7 ± 0.54) were statistically significant (both p < 0.001).
CONCLUSION: Our results suggest that higher 68Ga-PSMA-11 accumulation in the central zone than in the transition and peripheral zones is normal, and leads to a pattern resembling "Mickey Mouse ears" on 68Ga-PSMA-11 PET. This pattern could be helpful in avoiding false-positive interpretations of PET scans.

Entities:  

Keywords:  False-positive; Normal distribution; PET/MR; Prostate cancer; Staging

Mesh:

Substances:

Year:  2018        PMID: 29523924     DOI: 10.1007/s00259-018-3979-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

1.  PET/MR Outperforms PET/CT in Suspected Occult Tumors.

Authors:  Tetsuro Sekine; Felipe de Galiza Barbosa; Bert-Ram Sah; Cäcilia E Mader; Gaspar Delso; Irene A Burger; Paul Stolzmann; Edwin E Ter Voert; Gustav K von Schulthess; Patrick Veit-Haibach; Martin W Huellner
Journal:  Clin Nucl Med       Date:  2017-02       Impact factor: 7.794

2.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

3.  Direct comparison of PI-RADS version 2 and version 1 regarding interreader agreement and diagnostic accuracy for the detection of clinically significant prostate cancer.

Authors:  Anton S Becker; Alexander Cornelius; Cäcilia S Reiner; Daniel Stocker; Erika J Ulbrich; Borna K Barth; Ashkan Mortezavi; Daniel Eberli; Olivio F Donati
Journal:  Eur J Radiol       Date:  2017-07-21       Impact factor: 3.528

4.  68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.

Authors:  Christian Uprimny; Alexander Stephan Kroiss; Clemens Decristoforo; Josef Fritz; Elisabeth von Guggenberg; Dorota Kendler; Lorenza Scarpa; Gianpaolo di Santo; Llanos Geraldo Roig; Johanna Maffey-Steffan; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-31       Impact factor: 9.236

5.  Detailed mapping of prostate carcinoma foci: biopsy strategy implications.

Authors:  M E Chen; D A Johnston; K Tang; R J Babaian; P Troncoso
Journal:  Cancer       Date:  2000-10-15       Impact factor: 6.860

6.  (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer.

Authors:  Matthias Eiber; Stephan G Nekolla; Tobias Maurer; Gregor Weirich; Hans-Jürgen Wester; Markus Schwaiger
Journal:  Abdom Imaging       Date:  2015-08

7.  Normal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications.

Authors:  Hebert Alberto Vargas; Oguz Akin; Tobias Franiel; Debra A Goldman; Kazuma Udo; Karim A Touijer; Victor E Reuter; Hedvig Hricak
Journal:  Radiology       Date:  2012-03       Impact factor: 11.105

8.  Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.

Authors:  C Marchal; M Redondo; M Padilla; J Caballero; I Rodrigo; J García; J Quian; D G Boswick
Journal:  Histol Histopathol       Date:  2004-07       Impact factor: 2.303

9.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Authors:  Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-12       Impact factor: 9.236

Review 10.  Multiparametric magnetic resonance imaging of the prostate-a basic tutorial.

Authors:  Miguel C Cabarrus; Antonio C Westphalen
Journal:  Transl Androl Urol       Date:  2017-06
View more
  7 in total

1.  68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement.

Authors:  Daniela A Ferraro; Andreas M Hötker; Olivio F Donati; Irene A Burger; Anton S Becker; Iliana Mebert; Riccardo Laudicella; Anka Baltensperger; Niels J Rupp; Jan H Rueschoff; Julian Müller; Ashkan Mortezavi; Marcelo T Sapienza; Daniel Eberli
Journal:  Eur J Hybrid Imaging       Date:  2022-07-18

Review 2.  Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Authors:  Rubel Chakravarty; Cerise M Siamof; Ashutosh Dash; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-08-20

Review 3.  PET/MRI in prostate cancer: a systematic review and meta-analysis.

Authors:  Laura Evangelista; Fabio Zattoni; Gianluca Cassarino; Paolo Artioli; Diego Cecchin; Fabrizio Dal Moro; Pietro Zucchetta
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-08       Impact factor: 9.236

4.  Development and validation of 68Ga-PSMA-11 PET/CT-based radiomics model to detect primary prostate cancer.

Authors:  Shiming Zang; Shuyue Ai; Rui Yang; Pengjun Zhang; Wenyu Wu; Zhenyu Zhao; Yudan Ni; Qing Zhang; Hongbin Sun; Hongqian Guo; Ruipeng Jia; Feng Wang
Journal:  EJNMMI Res       Date:  2022-09-30       Impact factor: 3.434

5.  Metal artifact reduction in 68Ga-PSMA-11 PET/MRI for prostate cancer patients with hip joint replacement using multiacquisition variable-resonance image combination.

Authors:  Ken Kudura; Tobias Oblasser; Daniela A Ferraro; Caecilia E Mader; Lars Husmann; Kerstin Friedrich; Edwin E G W Ter Voert; Irene A Burger
Journal:  Eur J Hybrid Imaging       Date:  2020-04-09

6.  Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study

Authors:  Lebriz Uslu-Beşli; Barış Bakır; Sertaç Asa; Ekrem Güner; Çetin Demirdağ; Onur Erdem Şahin; Emre Karayel; Muhammet Sait Sağer; Haluk Burçak Sayman; Kerim Sönmezoğlu
Journal:  Mol Imaging Radionucl Ther       Date:  2019-09-06

7.  Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study.

Authors:  Daniel Eberli; Irene A Burger; Daniela A Ferraro; Anton S Becker; Benedikt Kranzbühler; Iliana Mebert; Anka Baltensperger; Konstantinos G Zeimpekis; Hannes Grünig; Michael Messerli; Niels J Rupp; Jan H Rueschoff; Ashkan Mortezavi; Olivio F Donati; Marcelo T Sapienza
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-23       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.